Edmond DE Rothschild Holding S.A. Has $5.73 Million Stake in Danaher Corporation $DHR

Key Points

• Edmond DE Rothschild Holding S.A. reduced its stake in Danaher Corporation by 20.1%, selling 7,028 shares, leaving it with 27,931 shares valued at approximately $5.7 million.
• Despite the sale, a number of hedge funds have increased their holdings in Danaher, with AQR Capital Management boosting its position by 98.3%.
• Analysts generally maintain a positive outlook on Danaher, with an average price target of $246.35 and several institutions reporting upgrades and price revisions for the stock.

Edmond DE Rothschild Holding S.A. cut its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 20.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,931 shares of the conglomerate's stock after selling 7,028 shares during the period. Edmond DE Rothschild Holding S.A.'s holdings in Danaher were worth $5,726,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of DHR. Coastal Bridge Advisors LLC grew its position in Danaher by 4.8% in the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after acquiring an additional 50 shares during the last quarter. Hills Bank & Trust Co lifted its stake in Danaher by 0.3% in the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after purchasing an additional 53 shares during the last quarter. Sageworth Trust Co boosted its position in Danaher by 2.3% in the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after buying an additional 54 shares in the last quarter. 1834 Investment Advisors Co. increased its holdings in shares of Danaher by 3.3% during the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock worth $342,000 after buying an additional 54 shares in the last quarter. Finally, Rakuten Securities Inc. lifted its stake in shares of Danaher by 33.3% in the 1st quarter. Rakuten Securities Inc. now owns 224 shares of the conglomerate's stock valued at $46,000 after acquiring an additional 56 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Trading Down 2.2%

DHR traded down $4.39 during trading on Tuesday, hitting $194.24. The company's stock had a trading volume of 3,344,624 shares, compared to its average volume of 4,138,020. The firm has a market capitalization of $139.09 billion, a P/E ratio of 41.33, a PEG ratio of 2.79 and a beta of 0.75. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock's fifty day moving average price is $201.95 and its 200-day moving average price is $199.23.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period in the prior year, the firm earned $1.72 earnings per share. Danaher's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Insider Buying and Selling

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 11.20% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on DHR shares. Robert W. Baird upped their target price on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. UBS Group cut their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Wells Fargo & Company decreased their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. Guggenheim reiterated a "buy" rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, July 23rd. Finally, Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a report on Friday, July 11th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $246.35.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.